Standard‐of‐care HIV pre‐exposure prophylaxis (PrEP) is highly efficacious, but uptake of
and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP …

When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of
HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and …

Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-
risk individuals from HIV-1 infection. Despite this record of effectiveness, concerns persist …

Pre-exposure prophylaxis (PrEP) prevents HIV infection. Robust evidence—first from pivotal
clinical trials [1, 2], then rigorous studies testing best-practice models of implementation [3 …

Objectives The past decade has seen tremendous progress in the development of
biomedical agents that are effective as pre-exposure prophylaxis (PrEP) for HIV prevention …

Trials of candidate agents for HIV pre-exposure prophylaxis (PrEP) might randomly assign
participants to be given a new PrEP agent or oral coformulated tenofovir disoproxil fumarate …

Once-daily preexposure prophylaxis (PrEP) is up to 99% effective in reducing the risk of
human immunodeficiency virus (HIV) acquisition [1–5]. Although PrEP has been approved …

Designing and conducting active-controlled trials of HIV pre-exposure prophylaxis (PrEP)
therapeutics are becoming challenging due to inconsistency of adherence across trials and …

More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …

Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years
where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling …